Corona Remedies Ltd IPO

The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.

Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.

The company derive a significant majority of its revenue from the company operations within India (constituting 96.34% and 96.33% of the company revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for the company products in India, or if its fail to successfully expand into international markets, the company business, results of operations, financial conditions and cash flows may be adversely affected.

A significant portion of the company domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of the company domestic sales for MAT June 2025). Any adverse developments affecting its sales in these regions could has an adverse effect on the company business, results of operations, financial condition and cash flows.

70.10% of Its domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect the company business, results of operations, financial condition and cash flows.

Its depend on third-party suppliers to procure the company raw materials and finished goods, with whom the company does not has long term contracts, with the company total purchases aggregating to 19.87% and 27.96% of its total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, the company rely on La Chandra Pharmalab Private Limited, its Associate and Group Company, for the supply of certain active pharmaceutical ingredients in the comapny women's healthcare therapeutic area. its cannot assure you that the company will be in a position to fully control or direct the operations of such suppliers to ensure an uninterrupted supply of raw materials and APIs.

As of June 30, 2025, with a portfolio of 71 brands, its held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If its unable to obtain trademarks for the company products and brands or protect other proprietary information, the company business, results of operations, financial condition and cash flows may be adversely affected.

The company required to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company operations. If its fail to obtain, maintain or renew the required licenses, permits and approvals, it may adversely affect the company business, results of operations, financial condition and cash flows.

Proceeds from the Offer will not be available to it.

As of June 30, 2025, its engaged 22 carrying and forwarding agents for the sale of the company products across the regions in which the company market its products, with the company five largest C&F agents contributing to 43.30% and 44.35% of Its revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025. The loss of the company C&F agents, the deterioration of their financial condition or prospects, a reduction in their demand for the company products or its inability to maintain and increase the number of the company arrangements for the distribution of its products could adversely affect the company business, results of operations, financial conditions and cash flows.